31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In women at higher risk of cognitive decline due to vascular disease or risk factors, adherence to a Mediterranean-style diet was not associated with subsequent 5-year cognitive change. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dogs develop cognitive decline and a progressive accumulation of oxidative damage. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Studies have yielded clues to the etiology and natural history of cognitive impairment in PD, but much remains unclear and effective therapies are needed. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Aging is associated with progressive changes in learning and memory. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The Mediterranean diet is currently considered a functional diet with an increasing amount of scientific evidence that supports its beneficial effects in human health. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Fish consumption may be associated with slower cognitive decline with age. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The combinations that were both highly prevalent and had the most detrimental effect on global cognition were: hearing loss and physical inactivity for the dyad (mean difference in change score = -0.07 SD; 95 % CI: -0.09 to -0.06; p < 0.001; effect size = -0.28), hearing loss, physical inactivity, and hypertension for the triad (mean difference in change score = -0.07; 95 % CI: -0.09 to -0.06; p < 0.001; effect size = -0.28), and hearing loss, physical inactivity, hypertension, and sleep disturbance for the tetrad (mean difference in change score = -0.05; 95 % CI: -0.07 to -0.03; p < 0.001; effect size = -0.20). 5 key findings →
Design: longitudinal study Participants: 30,097 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sarcopenia and its components were associated with baseline MMSE and MMSE changes. 5 key findings →
Design: cohort study Participants: 3,146 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 6321 participants (mean [SE] age, 56.1 [0.18] years at visit 1; n = 4077 women [57.8%]) were included. 5 key findings →
Design: cohort study Participants: 4,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A covariate-adjusted linear mixed model for the intention-to-treat sample (N = 353; mean age = 69.7) revealed a significant positive change in dementia literacy at 6 months (standardized change = 0.246; p = 0.012) and a significant improvement in self-efficacy at 12 months (standardized change = 0.157; p = 0.008). 5 key findings →
Design: longitudinal study Participants: 353 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Significant improvement over time was observed in aggregated domain specific composite scores of episodic and semantic memory and spatial abilities. 5 key findings →
Design: longitudinal study Participants: 155 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
117 participants have complete data (mean age: 73 ± 7.4). 5 key findings →
Design: cohort study Participants: 150 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Hierarchical-Circular Model of Biological Memory offers a unifying hypothesis for Alzheimer's disease and related dementias that bridges genetic, epigenetic, physiological, neuroimmune, and interoceptive processes across the lifespan. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants numbered 3334 and had a median age of 62 years. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The manuscript provides a thorough analysis of the neurovascular and metabolic processes that contribute to cognitive deterioration in patients with Type 2 diabetes (T2D). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Greater diversity of social participation was associated with better long-term cognitive maintenance among older adults with hypertension and/or diabetes. 5 key findings →
Design: longitudinal study Participants: 547 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Biological definitions of neuronal α-synuclein disease are advancing diagnosis beyond traditional clinical syndromes, but the trajectories preceding dementia and the influence of concomitant Alzheimer pathology remain uncertain. 3 key findings →
Design: longitudinal study Participants: 1,543 Evidence: moderate
Full summary, score breakdown and related studies → Original source
When stable individual differences are accounted for, depressive symptoms emerge as a stronger within-person temporal predictor of cognitive decline than physical activity. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Most plasma proteomic studies in Alzheimer’s disease (AD) compare cases and controls cross-sectionally, leaving unresolved which AD-associated proteins mark diagnostic states and which are linked to disease progression. 5 key findings →
Design: longitudinal study Participants: 13,449 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events